CB Insights March 17, 2025
From deal activity to top investors, we analyze the shifting landscape for AI in clinical trials to determine how the tech is transforming drug development for the better.
This is the third and final report in a 3-part series on how AI is reshaping discovery, preclinical, and clinical research in drug R&D. Read part 1 on the discovery phase and part 2 on preclinical development.
Clinical development represents one of pharma’s costliest and riskiest investments.
Trials average $55M each, per a study in JAMA Health Forum, and can take more than a decade to complete. However, over 90% of drugs still fail. AI is emerging as a game-changing force in clinical development, tackling its biggest pain points head-on.
For example,...
Today's Sponsors
Today's Sponsor